Advanced search

Cost-effectiveness analysis of bicalutamide (Casodex((TM))) for adjuvant treatment of early prostate cancer

(2004) VALUE IN HEALTH. 7(4). p.472-481
Author
Organization

Citation

Please use this url to cite or link to this publication:

Chicago
MOEREMANS, K, K CAEKELBERGH, and Lieven Annemans. 2004. “Cost-effectiveness Analysis of Bicalutamide (Casodex((TM))) for Adjuvant Treatment of Early Prostate Cancer.” Value in Health 7 (4): 472–481.
APA
MOEREMANS, K., CAEKELBERGH, K., & Annemans, L. (2004). Cost-effectiveness analysis of bicalutamide (Casodex((TM))) for adjuvant treatment of early prostate cancer. VALUE IN HEALTH, 7(4), 472–481.
Vancouver
1.
MOEREMANS K, CAEKELBERGH K, Annemans L. Cost-effectiveness analysis of bicalutamide (Casodex((TM))) for adjuvant treatment of early prostate cancer. VALUE IN HEALTH. BLACKWELL PUBLISHING INC; 2004;7(4):472–81.
MLA
MOEREMANS, K, K CAEKELBERGH, and Lieven Annemans. “Cost-effectiveness Analysis of Bicalutamide (Casodex((TM))) for Adjuvant Treatment of Early Prostate Cancer.” VALUE IN HEALTH 7.4 (2004): 472–481. Print.
@article{306049,
  author       = {MOEREMANS, K and CAEKELBERGH, K and Annemans, Lieven},
  issn         = {1098-3015},
  journal      = {VALUE IN HEALTH},
  language     = {eng},
  number       = {4},
  pages        = {472--481},
  publisher    = {BLACKWELL PUBLISHING INC},
  title        = {Cost-effectiveness analysis of bicalutamide (Casodex((TM))) for adjuvant treatment of early prostate cancer},
  volume       = {7},
  year         = {2004},
}

Web of Science
Times cited: